Anaes · Applied cardiovascular & respiratory physiology
Neuromuscular junction physiology
Also known as Neuromuscular junction · Acetylcholine receptor · End-plate potential · Nicotinic receptor · Acetylcholinesterase · Excitation-contraction coupling
The neuromuscular junction converts the motor nerve action potential into muscle contraction, and it is the site of action of the muscle relaxants and their reversal agents. The framework rests on five exam-critical ideas: the motor nerve action potential opens voltage-gated calcium channels in the terminal, and the calcium entry drives vesicle release of acetylcholine into the synaptic cleft; acetylcholine binds the nicotinic (muscle-type) receptor on the motor end-plate, a ligand-gated cation channel whose opening produces the end-plate potential; the end-plate potential reaches threshold and triggers a muscle action potential, after which acetylcholinesterase in the cleft terminates the signal; the muscle action potential is coupled to contraction by T-tubules, the dihydropyridine and ryanodine receptors, and calcium release from the sarcoplasmic reticulum; and the junction is the target of the neuromuscular blockers (depolarising suxamethonium, non-depolarising rocuronium), their reversal (neostigmine inhibiting acetylcholinesterase, sugammadex encapsulating rocuronium), and of disease (myasthenia gravis, Lambert-Eaton). Built on the miR-206/ACh-receptor NMJ study (Jiang 2026), the neostigmine-bronchospasm report (Sato 2026), the efgartigimod-myasthenia review (Jiang 2026), the eculizumab-myasthenia report (Li 2026), and the sugammadex-anaphylaxis and airway-oedema reports (Ishihara 2025, Habib 2026).
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Acetylcholine binds the NICOTINIC (muscle-type, Nm) receptor on the motor end-plate — a ligand-gated sodium channel; muscle relaxants, neostigmine and myasthenia all act at or through this receptor.
- Acetylcholinesterase in the synaptic cleft terminates the signal within milliseconds; inhibiting it (neostigmine) raises acetylcholine and reverses a non-depolarising block (and can cause muscarinic side-effects — bronchospasm, bradycardia — needing an anticholinergic).
- Suxamethonium is a DEPOLARISING blocker (persistent receptor activation → phase I block, fasciculations then flaccidity, potassium release); the non-depolarisers (rocuronium, vecuronium) COMPETITIVELY block the receptor.
- Sugammadex reverses rocuronium by ENCAPSULATION (a chemical reversal, not a receptor one) — it does not depend on acetylcholine, does not cause the muscarinic effects of neostigmine, but can itself cause anaphylaxis.
- Myasthenia gravis (antibodies against the ACh receptor, post-synaptic) fatigues and is sensitive to non-depolarisers and resistant to suxamethonium; Lambert-Eaton (pre-synaptic, reduced ACh release, paraneoplastic) improves with use and is resistant to both.
Meet the patient
A 45-year-old woman for elective cholecystectomy receives suxamethonium for rapid-sequence intubation. She fasciculates, goes flaccid — and does not breathe again for three hours. The train-of-four is flat. Your registrar reaches for neostigmine.[1]
This is the NMJ biting back. The same junction every relaxant targets is the one whose enzyme genetics, receptor upregulation, and disease states decide whether your patient wakes up breathing. Atypical butyrylcholinesterase is the diagnosis hiding in this vignette — and neostigmine is the wrong move in a phase I block.[1]
References6ShowHide
- [1]Jiang G, et al. The miR-206-3p/Cpeb1 axis delays acetylcholine receptor degradation and preserves neuromuscular junction stability in denervation-induced muscle atrophy Cell Mol Life Sci, 2026.PMID 42334613
- [2]Sato M, et al. Suspected Neostigmine-Associated Bronchospasm Complicated by Pulmonary Edema During General Anesthesia: A Case Report Cureus, 2026.PMID 42311723
- [3]Jiang L, et al. Efgartigimod for generalized myasthenia gravis: a comprehensive review of clinical evidence and future perspectives Front Neurol, 2026.PMID 42358938
- [4]Li YX, et al. Successful rescue therapy with eculizumab for probable tislelizumab-related MMM overlap syndrome with dual positivity for anti-acetylcholine receptor and anti-titin antibodies: a case report and literature review Front Immunol, 2026.PMID 42358974
- [5]Ishihara H, et al. Anaphylaxis After a Third Exposure to Sugammadex Anesth Prog, 2025.PMID 41905390
- [6]Habib R, et al. Sugammadex-Associated Delayed Laryngeal and Upper Airway Edema: A Novel Adverse Effect J Investig Med High Impact Case Rep, 2026.PMID 42113672